全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

植物雌激素在防治心肌缺血再灌注损伤的应用前景

Keywords: 心肌缺血再灌注损伤,植物雌激素

Full-Text   Cite this paper   Add to My Lib

Abstract:

心肌缺血再灌注损伤是心血管疾病领域研究的热点问题之一,目前临床上尚缺乏有效的防治手段。临床研究发现冠心病的绝经前女性患者要明显低于男性患者,说明雌激素在其发生发展过程中具有一定的作用,使雌激素替代疗法逐渐成为新的防治研究热点。大量植物雌激素应用于心血管疾病的预防治疗研究,以期消除合成类雌激素在治疗中副作用。该文总结了雌激素受体在心肌缺血再灌注损伤中的作用,雌激素替代疗法的应用及局限性,以及植物雌激素在其防治过程中的应用前景,以期为开发安全、有效的新型药物提供思路和参考。

References

[1]  WHO. Cardiovascular diseases(CVDs)[DB/OL].[2004-12-01] http://www.who.int/cardiovascular_diseases/en/2015-01.
[2]  Bernink F, Timmers L, Beek A M, et al. Progression in attenuating myocardial reperfusion injury: an overview[J]. Int J Cardiol, 2014,170(3): 261.
[3]  Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury[J]. Physiol Rev, 2008, 88(2): 581.
[4]  Mendelsohn M E, Karas R H. Molecular and cellular basis of cardiovascular gender differences[J]. Science, 2005,308(5728): 1583.
[5]  Deschamps A M, Murphy E, Sun J. Estrogen receptor activation and cardioprotection in ischemia reperfusion injury[J]. Trends Cardiovasc Med, 2010,20(3):73.
[6]  Komesaroff P A, Sudhir K. Estrogens and human cardiovascular physiology[J]. Reprod Fertil Dev, 2001,13(4): 261.
[7]  Simoncini T, Hafezi-Moghadam A, Brazil D P, et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase[J]. Nature, 2000, 407(6803): 538.
[8]  Filardo E J, Quinn J A, Bland K I, et al. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF[J]. Mol Endocrinol, 2000,14(10):1649.
[9]  Huang C, Gu H, Wang Y, et al. Estrogen-induced SDF-1 production is mediated by estrogen receptor-α in female hearts after acute ischemia and reperfusion[J]. Surgery, 2011,150(2):197.
[10]  Cong B, Xu Y, Sheng H, et al. Cardioprotection of 17β-estradiol against hypoxia/reoxygenation in cardiomyocytes is partly through up-regulation of CRH receptor type 2[J]. Mol Cell Endocrinol, 2014, 382(1): 17.
[11]  Fukumoto T, Tawa M, Yamashita N, et al. Protective effects of 17beta-estradiol on post-ischemic cardiac dysfunction and norepinephrine overflow through the non-genomic estrogen receptor/nitric oxide-mediated pathway in the rat heart[J]. Eur J Pharm, 2013,699(1/3):74.
[12]  Sun J, Murphy E. Protein S-nitrosylation and cardioprotection[J]. Circ Res, 2010,106(2):285.
[13]  Lin J, Steenbergen C, Murphy E, et al. Estrogen receptor-β activation results in S-nitrosylation of proteins involved in cardioprotection[J]. Circulation, 2009,120(3): 245.
[14]  Patten R D, Pourati I, Aronovitz M J, et al. 17β-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling[J]. Circul Res, 2004,95(7): 692.
[15]  Deschamps A M, Murphy E. Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats[J]. Am J Physiol Heart Circ Physiol, 2009, 297(5): H1806.
[16]  Wang Y, Sun J, Liu C, et al. Protective effects of crocetin pretreatment on myocardial injury in an ischemia/reperfusion rat model[J]. Eur J Pharm, 2014,741:290.
[17]  Gulati P, Muthuraman A, Jaggi A S, et al. Neuroprotective effect of gadolinium: a stretch-activated calcium channel blocker in mouse model of ischemia-reperfusion injury[J]. Naunyn Schmiedebergs Arch Pharmacol, 2013, 386(3): 255.
[18]  Calvert J W, Condit M E, Aragón J P, et al. Exercise protects against myocardial ischemia-reperfusion injury via stimulation of β3-adrenergic receptors and increased nitric oxide signaling: role of nitrite and nitrosothiols[J]. Circul Res, 2011,108(12): 1448.
[19]  Jia D. The protective effect of mitochondrial ATP-sensitive K+ channel opener, nicorandil, combined With Na+/Ca2+ exchange blocker KB-R7943 on myocardial ischemia-reperfusion injury in rat[J]. Cell Biochem Biophys, 2011,60(3): 219.
[20]  Lerner D J, Kannel W B. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population[J]. Am Heart J, 1986,111(2): 383.
[21]  Kolodgie F D, Farb A, Litovsky S H, et al. Myocardial protection of contractile function after global ischemia by physiologic estrogen replacement in the ovariectomized rat[J]. J Mol Cell Card, 1997, 29(9): 2403.
[22]  Kang L S, Chen B, Reyes R A, et al. Aging and estrogen alter endothelial reactivity to reactive oxygen species in coronary arterioles[J]. Am J Physiol Heart Circ Physiol, 2011, 300(6): H2105.
[23]  Li H Y, Bian J S, Kwan Y W, et al. Enhanced responses to 17beta-estradiol in rat hearts treated with isoproterenol: involvement of a cyclic AMP-dependent pathway[J]. J Pharmacol Exp Ther, 2000, 293(2): 592.
[24]  Wang M, Tsai B M, Reiger K M,et al. 17-β-Estradiol decreases p38 MAPK-mediated myocardial inflammation and dysfunction following acute ischemia[J]. J Mol Cell Card, 2006,40(2): 205.
[25]  Narod S A. Hormone replacement therapy and the risk of breast cancer[J]. Nat Rev Clin Oncol, 2011, 8(11): 669.
[26]  Writing G F T W. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the womens health initiative randomized controlled trial[J]. J Am Med Assoc, 2002, 288(3): 321.
[27]  Chlebowski R T, Hendrix S L, Langer R D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the womens health initiative randomized trial[J]. J Am Med Assoc, 2003,289(24): 3243.
[28]  Saxena R, Dwivedi A. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective[J]. Med Res Rev, 2012, 32(1): 166.
[29]  Rossouw J E, Anderson G L, Prentice R L, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\'s Health Initiative randomized controlled trial[J]. J Am Med Assoc, 2002, 288(3): 321.
[30]  L\'Hermite M. HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT[J]. Climacteric, 2013, 16(Suppl 1): 44.
[31]  Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study[J]. Circulation, 2007, 115(7): 840.
[32]  Usui T. Pharmaceutical prospects of phytoestrogens[J]. Endocr J, 2006, 53(1): 7.
[33]  Strauss L, Santti R, Saarinen N, et al. Dietary phytoestrogens and their role in hormonally dependent disease[J]. Toxicol Lett, 1998,102/103:349.
[34]  Bairey Merz C N, Johnson B D, Braunstein G D, et al. Phytoestrogens and lipoproteins in women[J]. J Clin Endocrinol Metab, 2006, 91(6): 2209.
[35]  Krul E S, Mauro L, Mukherjea R. Justification for soy protein to still have a category \'A\' coronary heart disease risk reduction health claim[J]. Trends Food Sci Techn, 2014,36(1): 55.
[36]  Heldring N, Pike A, Andersson S, et al. Estrogen receptors: how do they signal and what are their targets[J]. Physiol Rev, 2007, 87(3): 905.
[37]  Ma Y, Lovekamp-Swan T, Bekele W, et al. Hypoxia-inducible factor and vascular endothelial growth factor are targets of dietary soy during acute stroke in female rats[J]. Endocrinology, 2013, 154(4): 1589.
[38]  Jin H, Yang Y, Song Y, et al. Protective roles of quercetin in acute myocardial ischemia and reperfusion injury in rats[J]. Mol Biol Rep, 2012, 39(12): 11005.
[39]  Yamazaki K G, Romero-Perez D, Barraza-Hidalgo M, et al. Short-and long-term effects of (-)-epicatechin on myocardial ischemia-reperfusion injury[J]. Am J Physiol Heart Circ Physiol, 2008, 295(2): H761.
[40]  Wan L L, Xia J, Ye D, et al. Effects of quercetin on gene and protein expression of NOX and NOS after myocardial ischemia and reperfusion in rabbit[J]. Cardiovasc Therap, 2009, 27(1): 28.
[41]  Brookes P S, Digerness S B, Parks D A, et al. Mitochondrial function in response to cardiac ischemia-reperfusion after oral treatment with quercetin[J]. Free Radic Biol Med, 2002, 32(11):1220.
[42]  Renaud S D, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease[J]. The Lancet, 1992, 339(8808):1523.
[43]  Hung L, Su M, Chen J. Resveratrol protects myocardial ischemia-reperfusion injury through both NO-dependent and NO-independent mechanisms[J]. Free Radic Biol Med, 2004, 36(6):774.
[44]  Dos Santos K C, Braga C P, Barbanera P O, et al. Cardiac energy metabolism and oxidative stress biomarkers in diabetic rat treated with resveratrol[J]. PloS ONE, 2014, 9(7):e102775.
[45]  Mao S, Wang Y, Zhang M, et al. Phytoestrogen, tanshinone ⅡA diminishes collagen deposition and stimulates new elastogenesis in cultures of human cardiac fibroblasts[J]. Exp Cell Res, 2014, 323(1): 189.
[46]  Wei B, Li W W, Ji J, et al. The cardioprotective effect of sodium tanshinone ⅡA sulfonate and the optimizing of therapeutic time window in myocardial ischemia/reperfusion injury in rats[J]. Atherosclerosis, 2014, 235(2): 318.
[47]  李欣,袁建平,刘昕,等. 木脂素——一类重要的天然植物雌激素[J].中国中药杂志,2006,31(24):2021.
[48]  Yehuda I, Madar Z, Szuchman Sapir A, et al. Glabridin, a phytoestrogen from licorice root, up-regulates manganese superoxide dismutase, catalase and paraoxonase 2 under glucose stress[J]. Phytother Res, 2011, 25(5): 659.
[49]  Li C, Guo Y, Dong X, et al. Ethanolic extract of rhizome of Ligusticum chuanxiong Hort.(chuanxiong) enhances endothelium-dependent vascular reactivity in ovariectomized rats fed with high-fat diet[J]. Food Function, 2014.
[50]  Alexander V S. Phytoestrogens and their effects[J]. Eur J Pharm, 2014, 741: 230.
[51]  Bolli R, Becker L, Gross G, et al. Myocardial protection at a crossroads the need for translation into clinical therapy[J]. Circ Res, 2004, 95(2):125.
[52]  赵丕文,王大伟,牛建昭,等. 红花等10种中药的植物雌激素活性研究[J].中国中药杂志, 2007, 32(5):436.
[53]  王若光,尤昭玲,冯光荣.中药植物性雌激素研究[J].中国中西医结合杂志,2004, 24(2):169.
[54]  陈嫱,李文兰,丁振铎,等.中药植物雌激素双向调节的机制研究[J].哈尔滨商业大学学报:自然科学版, 2014,127(2):138.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133